Isotechnika Announces Changes to Senior Management and Board of Directors MarketWatch (press release) This change is designed to allow Dr. Foster to continue to focus firmly on Phase 3 development activities of the Company's leading product candidate, voclosporin, for the prevention of kidney transplant rejection, and to continue licensing opportunity ... |
